Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model

CLSI and EUCAST susceptibility breakpoints for voriconazole and Candida albicans differ by one dilution (≤0.125 and ≤0.06 mg/liter, respectively) whereas the epidemiological cutoff values for EUCAST (ECOFF) and CLSI (ECV) are the same (0.03 mg/liter). We therefore determined the pharmacokinetic/phar...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Beredaki, Maria-Ioanna, Georgiou, Panagiota-Christina, Siopi, Maria, Kanioura, Lamprini, Andes, David, Arendrup, Maiken Cavling, Mouton, Johan W., Meletiadis, Joseph
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2020
Sujets:
Susceptibility
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269500/
https://ncbi.nlm.nih.gov/pubmed/32229492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00170-20
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires